Jun 2026 (Q2 FY26) — Aug 6, 2026
Xenon Pharmaceuticals Q2 FY26 — Azetukalner NDA Submission and Pipeline Advancement
Read the full callXenon Pharmaceuticals (XENE) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Xenon Pharmaceuticals earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.00 | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -111 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Guidance
What management said, and what became of it
7 of 7 judged targets kept · 5 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| AZK NDA submission (focal onset seizures) to FDA | Submit NDA for azetukalner (FOS) to FDA in Q3 2026 | Mar 2026 | we, therefore, remain on track to submit our NDA this quarter as planned and are encouraged by our continued engagement with the agency | On Track |
| Nav1.1 program (Dravet syndrome): candidate entering IND-enabling studies | Lead Nav1.1 candidate to enter IND-enabling studies in 2025 | Mar 2025 | IND-enabling studies for this program are currently ongoing. | Achieved |
5 of Xenon Pharmaceuticals Inc.'s 12 targets are still open. See which are on track and which have gone quiet. The 2 above are the free sample; 10 more targets are in the full ledger.
Claimed
- Successful pre-NDA meeting with FDA for Azetukalner (AZK) for focal seizures, on track for submission later this quarter.
- X-TOLE2 Phase 3 results for AZK demonstrated best placebo-adjusted efficacy in FOS, with 91% reduction in monthly seizure frequency for long-term patients.
- Cash, cash equivalents, and marketable securities of $1.2 billion, providing runway into 2029.
- Advancement of two Nav1.7 pain candidates (XEN1701 and XEN1720) and a Kv7 pain candidate (XEN1120) into Phase 1 studies, with XEN1701 and XEN1120 nearing completion and showing exposures predictive of efficacy.
- Strong enthusiasm from general neurologists and epilepsy specialists for AZK's profile, including novel mechanism, rapid onset, once-daily dosing, and no titration.
Qualified
Price
$35.08 +4.75% · +$1.59
Performance −15.7% 1Y
1Y: $41.63 on 17 Oct 2025 → $35.08. High $70.96 (9 Jul 2026), low $33.49 (16 Oct 2026).
- Previous close
- $33.49
- 52-week range
- $33.49 – $70.96
- One year
- −19.24%
Overview
- Symbol
- XENE
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
7 of 7 judged targets kept · 5 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| AZK NDA submission (focal onset seizures) to FDA | Submit NDA for azetukalner (FOS) to FDA in Q3 2026 | Mar 2026 | we, therefore, remain on track to submit our NDA this quarter as planned and are encouraged by our continued engagement with the agency | On Track |
| Nav1.1 program (Dravet syndrome): candidate entering IND-enabling studies | Lead Nav1.1 candidate to enter IND-enabling studies in 2025 | Mar 2025 | IND-enabling studies for this program are currently ongoing. | Achieved |
Claimed
- Successful pre-NDA meeting with FDA for Azetukalner (AZK) for focal seizures, on track for submission later this quarter.
- X-TOLE2 Phase 3 results for AZK demonstrated best placebo-adjusted efficacy in FOS, with 91% reduction in monthly seizure frequency for long-term patients.
- Cash, cash equivalents, and marketable securities of $1.2 billion, providing runway into 2029.
- Advancement of two Nav1.7 pain candidates (XEN1701 and XEN1720) and a Kv7 pain candidate (XEN1120) into Phase 1 studies, with XEN1701 and XEN1120 nearing completion and showing exposures predictive of efficacy.
- Strong enthusiasm from general neurologists and epilepsy specialists for AZK's profile, including novel mechanism, rapid onset, once-daily dosing, and no titration.
Qualified
The full ledger
Open Xenon Pharmaceuticals Inc.’s full ledger
A free account opens 5 company ledgers a month. All 12 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
Xenon Pharmaceuticals Q1 FY26 — Strong X-TOLE2 Data and Extended Cash Runway
Read the full callEvery analysed call
Xenon Pharmaceuticals earnings calls (XENE)
Financials
What the filings say
Net profit, year on year: −31% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | -74 | -77 | -73 | -94 | -96 | -110 | -112 | -123 |
| Operating margin | — | — | −969.8% | — | — | — | — | — |
| Other income | 11 | 8 | 8 | 9 | 6 | 5 | 7 | 12 |
| Profit before tax | -63 | -70 | -65 | -85 | -90 | -105 | -105 | -111 |
| Tax rate | 0.5% | 5.5% | −0.7% | 0.7% | −0.8% | −0.5% | 2.5% | 0.5% |
| Net profit | -63 | -66 | -65 | -85 | -91 | -105 | -102 | -111 |
| EPS ($ per share) | -0.81 | — | -0.83 | -1.07 | -1.15 | — | -1.17 | -1.11 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 266 | 294 | 398 | 783 | 1,065 | 1,436 | 1,457 | 1,599 |
| Reserves | -208 | -250 | -278 | -357 | -483 | -665 | -899 | -1,245 |
| Total liabilities | 19 | 56 | 18 | 22 | 33 | 37 | 43 | 51 |
| Fixed assets | 1 | 2 | 4 | 4 | 7 | 10 | 10 | 9 |
| Investments | 52 | 117 | 132 | 376 | 535 | 489 | 484 | 350 |
| Total assets | 122 | 148 | 189 | 572 | 754 | 965 | 798 | 633 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -35 | -5 | -48 | -70 | -101 | -151 | -181 | -279 |
| Cash from investing | -29 | -66 | -17 | -247 | -293 | -111 | 165 | 218 |
| Cash from financing | 112 | 28 | 86 | 448 | 278 | 354 | 12 | 117 |
| Net cash flow | 47 | -43 | 20 | 131 | -118 | 91 | -6 | 56 |
| Capital expenditure | -1 | -1 | -3 | -2 | -3 | -6 | -3 | -1 |
| Free cash flow | -35 | -6 | -51 | -72 | -104 | -157 | -184 | -280 |
Insider filings
51 filings between Nov 28, 2025 and Oct 15, 2026.
Open market
decisions to buy or sellPurchases
$1.68M
2 purchases by 2 insiders
Sales
$21.97M
26 sales by 6 insiders
96% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 21
- Option exercise — converted options into shares
- 2
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| MORTIMER IAN | $1.12M | $20.29M | Sep 30, 2026 |
| KENNEY CHRISTOPHER JOHN | — | $670.3K | Aug 28, 2026 |
| GANNON STEVEN | — | $640.5K | Aug 11, 2026 |
| Kelly Thomas Patrick | $559.7K | — | Sep 30, 2026 |
| DiFabio Andrea | — | $230.8K | Mar 13, 2026 |
| PATOU GARY | — | $70.3K | Jun 5, 2026 |
| Cannon Gillian | — | $63.2K | Jun 5, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 15, 2026 | Kelly Thomas Patrick Chief Financial Officer | Option exercise | 7,500 | — |
| Sep 30, 2026 | Kelly Thomas Patrick Chief Financial Officer | Purchase | 15,000 | $559.7K |
| Sep 30, 2026 | MORTIMER IAN PRESIDENT & CEO | Purchase | 30,000 | $1.12M |
| Sep 1, 2026 | Svoronos Dawn Director | Option exercise | 5,144 | $41.9K |
| Aug 28, 2026 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Sale 10b5-1 plan | 6,368 | $383.1K |
| Aug 28, 2026 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Sale 10b5-1 plan | 700 | $42.7K |
| Aug 11, 2026 | GANNON STEVEN Director | Sale | 10,000 | $640.6K |
| Jun 5, 2026 | PATOU GARY Director | Sale 10b5-1 plan | 1,322 | $70.3K |
| Jun 5, 2026 | Cannon Gillian Director | Sale 10b5-1 plan | 1,190 | $63.2K |
| Jun 1, 2026 | GANNON STEVEN Director | Option exercise | 2,645 | — |
| Jun 1, 2026 | GAROFALO ELIZABETH A. Director | Option exercise | 2,645 | — |
| Jun 1, 2026 | Gover Justin D. Director | Option exercise | 2,645 | — |
| Jun 1, 2026 | PATOU GARY Director | Option exercise | 2,645 | — |
| Jun 1, 2026 | Machado Patrick Director | Option exercise | 2,645 | — |
| Jun 1, 2026 | Svoronos Dawn Director | Option exercise | 2,645 | — |
| Jun 1, 2026 | Cannon Gillian Director | Option exercise | 2,645 | — |
| Jun 1, 2026 | GANNON STEVEN Director | Tax withheld | 1,416 | $75.6K |
| Jun 1, 2026 | Svoronos Dawn Director | Tax withheld | 1,416 | $75.6K |
| May 12, 2026 | GANNON STEVEN Director | Option exercise | 3,500 | $25.8K |
| Mar 13, 2026 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Sale 10b5-1 plan | 1,410 | $77.9K |
| Mar 13, 2026 | DiFabio Andrea Chief Legal Officer | Sale 10b5-1 plan | 1,342 | $74.1K |
| Mar 13, 2026 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 7,308 | $403.6K |
| Mar 12, 2026 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Option exercise 10b5-1 plan | 3,750 | — |
| Mar 12, 2026 | DiFabio Andrea Chief Legal Officer | Option exercise 10b5-1 plan | 3,750 | — |
| Mar 12, 2026 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 plan | 12,500 | — |
| Mar 10, 2026 | DiFabio Andrea Chief Legal Officer | Sale 10b5-1 plan | 2,607 | $156.7K |
| Mar 10, 2026 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 11,269 | $677.4K |
| Mar 10, 2026 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Sale 10b5-1 plan | 2,771 | $166.6K |
| Mar 9, 2026 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 2,449 | $150.0K |
| Mar 9, 2026 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 61,652 | $3.70M |
| Mar 9, 2026 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 plan | 65,000 | $613.6K |
| Mar 9, 2026 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 plan | 75,000 | $630.0K |
| Mar 9, 2026 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 21,791 | $1.28M |
| Mar 9, 2026 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 31,694 | $1.90M |
| Mar 9, 2026 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 21,515 | $1.30M |
| Mar 9, 2026 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 plan | 25,000 | $77.5K |
| Mar 9, 2026 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 12,479 | $742.5K |
| Mar 9, 2026 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 10,072 | $609.1K |
| Mar 9, 2026 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 plan | 105,000 | $498.8K |
| Mar 9, 2026 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 43,348 | $2.57M |
| Mar 9, 2026 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 65,000 | $4.03M |
| Mar 9, 2026 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 plan | 20,000 | — |
| Mar 9, 2026 | DiFabio Andrea Chief Legal Officer | Option exercise 10b5-1 plan | 7,500 | — |
| Mar 9, 2026 | KENNEY CHRISTOPHER JOHN Chief Medical Officer | Option exercise 10b5-1 plan | 7,500 | — |
| Jan 2, 2026 | MORTIMER IAN PRESIDENT & CEO | Option exercise 10b5-1 plan | 40,000 | $299.6K |
| Jan 2, 2026 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 37,938 | $1.68M |
| Jan 2, 2026 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 2,062 | $92.6K |
| Dec 8, 2025 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 2,010 | $93.1K |
| Dec 8, 2025 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 8,820 | $402.1K |
| Dec 5, 2025 | MORTIMER IAN PRESIDENT & CEO | Sale 10b5-1 plan | 14,375 | $647.3K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Xenon Pharmaceuticals Inc.
Free account. Everything above stays public.
Write why you follow Xenon Pharmaceuticals Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading